Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.
Get this delivered to your inbox, and more info about our products and services.
Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the…
Mike Doustdar, new CEO of Ozempic maker, Novo Nordisk discusses his strategy for the future of the company.
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S.…
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
Renault, Elekta, Tietoevry and a number of others have recently reset expectations with investors.
